167 related articles for article (PubMed ID: 33797759)
1. Nutraceuticals in fibroid management after ulipristal acetate administration: An observational study on patients' compliance.
Tinelli A; Gustapane S; D'Oria O; Licchelli M; Panese G
Int J Gynaecol Obstet; 2022 Jan; 156(1):133-138. PubMed ID: 33797759
[TBL] [Abstract][Full Text] [Related]
2. Role of ethnicity in treating uterine fibroids with ulipristal acetate.
Murji A; Crosier R; Chow T; Ye XY; Shirreff L
Fertil Steril; 2016 Oct; 106(5):1165-1169. PubMed ID: 27336213
[TBL] [Abstract][Full Text] [Related]
3. Ulipristal acetate decreases transforming growth factor β3 serum and tumor tissue concentrations in patients with uterine fibroids.
Ciebiera M; Włodarczyk M; Wrzosek M; Słabuszewska-Jóźwiak A; Nowicka G; Jakiel G
Fertil Steril; 2018 Mar; 109(3):501-507.e2. PubMed ID: 29525690
[TBL] [Abstract][Full Text] [Related]
4. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
5. Management of symptomatic uterine fibroids after ulipristal acetate suspension and identification of high risk patients for surgery at 6-months of follow-up.
Nicolás I; Martínez-Zamora MÁ; Gracia M; Carrion A; Feixas G; Bernal L; Quintas L; Rius M; Castelo-Branco C; Carmona F
Gynecol Endocrinol; 2021 Sep; 37(9):831-835. PubMed ID: 34044726
[TBL] [Abstract][Full Text] [Related]
6. The Biological Impact of Ulipristal Acetate on Cellular Networks Regulating Uterine Leiomyoma Growth.
Tinelli A; Kosmas IP; Mynbaev OA; Malvasi A; Sparic R; Vergara D
Curr Pharm Des; 2020; 26(3):310-317. PubMed ID: 31987017
[TBL] [Abstract][Full Text] [Related]
7. 1,25 Dihydroxyvitamin D3 Enhances the Antifibroid Effects of Ulipristal Acetate in Human Uterine Fibroids.
Ali M; Shahin SM; Sabri NA; Al-Hendy A; Yang Q
Reprod Sci; 2019 Jun; 26(6):812-828. PubMed ID: 30514160
[TBL] [Abstract][Full Text] [Related]
8. A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids.
Ghonim M; Magdy R; Sabbour M; Ghonim M; Nabhan A
Int J Gynaecol Obstet; 2019 Aug; 146(2):141-148. PubMed ID: 31127621
[TBL] [Abstract][Full Text] [Related]
9. Which is the destiny of ulipristal acetate for uterine fibroids? A commentary on the Italian medicines agency (AIFA) pronouncements.
Indraccolo U; Conzadori S; Greco P
Recenti Prog Med; 2019 Feb; 110(2):98-99. PubMed ID: 30843536
[TBL] [Abstract][Full Text] [Related]
10. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital.
Woodhead N; Pounds R; Irani S; Pradhan P
J Obstet Gynaecol; 2018 Aug; 38(6):813-817. PubMed ID: 29526144
[TBL] [Abstract][Full Text] [Related]
11. Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial.
Osuga Y; Nakano Y; Yamauchi Y; Takanashi M
Fertil Steril; 2021 Jul; 116(1):189-197. PubMed ID: 33715871
[TBL] [Abstract][Full Text] [Related]
12. Ulipristal acetate for uterine fibroid-related symptoms.
Puchar A; Luton D; Koskas M
Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
[TBL] [Abstract][Full Text] [Related]
13. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.
Yun BS; Seong SJ; Jung YW; Kim ML; Bae HS; Kim MK; Shim SS
Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():133-136. PubMed ID: 29602142
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.
Donnez J; Hudecek R; Donnez O; Matule D; Arhendt HJ; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Terrill P; Osterloh I; Loumaye E
Fertil Steril; 2015 Feb; 103(2):519-27.e3. PubMed ID: 25542821
[TBL] [Abstract][Full Text] [Related]
15. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
16. Phase III long-term study to evaluate the efficacy and safety of ulipristal acetate in Japanese patients with uterine fibroids.
Osuga Y; Nakano Y; Yamauchi Y; Murakawa H
J Obstet Gynaecol Res; 2021 Sep; 47(9):3269-3278. PubMed ID: 34109697
[TBL] [Abstract][Full Text] [Related]
17. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
18. Potential synergism between ulipristal acetate and vitamin D3 in uterine fibroid pharmacotherapy - 2 case studies.
Ciebiera M; Męczekalski B; Łukaszuk K; Jakiel G
Gynecol Endocrinol; 2019 Jun; 35(6):473-477. PubMed ID: 30632825
[TBL] [Abstract][Full Text] [Related]
19. Differences in fibroid vascularity after three months of pre-treatment with leuprolide acetate or ulipristal acetate: A pilot study.
Frijlingh M; De Milliano I; Hehenkamp WJK; Huirne JAF
Eur J Obstet Gynecol Reprod Biol; 2020 Feb; 245():186-192. PubMed ID: 31679806
[TBL] [Abstract][Full Text] [Related]
20. Long-term medical management of uterine fibroids with ulipristal acetate.
Donnez J; Donnez O; Matule D; Ahrendt HJ; Hudecek R; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Loumaye E
Fertil Steril; 2016 Jan; 105(1):165-173.e4. PubMed ID: 26477496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
